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Abstract
Background: Previous studies provide evidence that adipokine leptin increases production of catabolic and
proinflammatory factors in chondrocytes and serves as a link between obesity and osteoarthritis (OA). However,
the magnitude of the response to leptin treatment varies greatly between chondrocytes from different donor
patients. In the present study, we investigated the regulatory role of suppressor of cytokine signaling-3 (SOCS-3)
in the leptin-induced responses in OA cartilage.
Methods: Cartilage and synovial fluid samples from 97 patients with OA undergoing knee replacement surgery
were collected. Cartilage samples were cultured with leptin (10 μg/ml), and the levels of proinflammatory and
catabolic factors in synovial fluid and in the cartilage culture media, and SOCS-3 expression in the cartilage were
measured. The role of SOCS-3 in leptin signaling was further studied in H4 murine chondrocytes by downregulating
SOCS-3 with siRNA.
Results: Leptin-induced expression of matrix metalloproteinases MMP-1, MMP-3, MMP-13, interleukin-6 (IL-6), inducible
nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were higher in the cartilage samples with low SOCS-3
expression. Accordingly, downregulation of SOCS-3 by siRNA in H4 chondrocytes led to enhanced leptin-induced
expression of MMP-3, MMP-13, IL-6 and iNOS. Synovial fluid leptin was associated positively, and cartilage SOCS-3
negatively with synovial fluid levels of MMPs in a multivariate model in obese (body mass index (BMI) >30 kg/m2) but
not in non-obese (BMI <30 kg/m2) patients.
Conclusions: Our results show, for the first time, that SOCS-3 regulates leptin-induced responses in cartilage, and could
thus be a future drug target in the treatment or prevention of OA, especially in obese patients.
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Background
Adipokines are cytokine-like hormones produced by
adipose tissue and originally discovered to regulate en-
ergy metabolism [1, 2]. Their role in inflammation and
obesity-related disease, such as type 2 diabetes mellitus
and cardiovascular disease, and also in rheumatic dis-
ease has attracted increasing interest during the past
decade. Leptin was first characterized in 1994 [3] and
to date it is probably the most studied adipokine. The
circulating levels of leptin are closely associated with
the amount of stored body fat and with body mass
index (BMI) [4]. Leptin is, however, not only produced
by adipose tissue, but also by several other tissues, in-
cluding cartilage and other joint tissues [5–7]. Interest-
ingly, synovial fluid leptin levels are also correlated
with BMI and leptin expression in chondrocytes is
increased in obese individuals with OA [5, 6, 8]. The
expression of leptin and its functional receptor Ob-Rb
is also reported to be increased in chondrocytes in OA,
in comparison to healthy chondrocytes [6].
Obesity is a major risk factor for OA [9]. Traditionally
obesity has been thought to explain the risk of developing
OA due to increased wear-and-tear on weight-bearing
joints. However, obesity is also a risk factor for hand OA
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[10], which points to a systemic factor or factors that
mediate the obesity-related impact on cartilage. Leptin,
with its strong positive association with body fat stores,
fits well in this picture; in fact, increasing evidence
supports the role of leptin as a significant factor in the
pathogenesis of OA. Leptin has been shown to have direct
proinflammatory and catabolic effects on cartilage in ex-
perimental settings. We and others have previously shown
that leptin enhances production of catabolic enzymes,
including matrix metalloproteinase 1 (MMP-1), MMP-2,
MMP-3, MMP-9, MMP-13, a disintegrin and metallopro-
teinase with thrombospondin motifs 4 (ADAMTS-4) and
ADAMTS-5 and proinflammatory mediators, such as
nitric oxide (NO), interleukin 6 (IL-6), IL-1β, IL-8 and
prostaglandin E2 (PGE2) in chondrocytes, synoviocytes
and in cartilage [6, 11–19]. These findings suggest that
leptin is not only a bystander of cartilage breakdown, but
an active detrimental factor in the pathogenesis of OA.
According to our experience, cartilage from different
donor patients respond to leptin treatment in a quite ver-
satile manner: some of the samples produce large amounts
of catabolic/proinflammatory mediators like MMPs, IL-6
and NO following leptin treatment, while in some samples
leptin-induced changes in the production of these factors
are very small. Similar wide variation in the response to
leptin is also supported by other studies [17]. A study by
Pallu et al. showed that primary chondrocytes received
from obese patients with OA respond to smaller amounts
of leptin to enhance MMP-13 production than chon-
drocytes obtained from non-obese patients [17], suggesting
that obese individuals might be more susceptible to the
harmful effects of leptin on cartilage. However, the mecha-
nisms regulating leptin responsiveness in chondrocytes
remain unknown.
Suppressor of cytokine signaling 3 (SOCS-3) belongs
to SOCS proteins, which are intracellular molecules that
have an important function of limiting excessive inflam-
matory activation of the innate and adaptive immune
system [20]. In inflammatory cells SOCS-3 expression is
induced by type I and type II cytokine receptors via the
JAK-STAT pathway. SOCS-3 binds to the gp130 subunit
of those receptors and inhibits the JAK-STAT pathway,
thus forming a negative feedback loop to limit cytokine
actions [21]. Interestingly, SOCS-3 is also involved in
regulating leptin responsiveness in the central nervous
system (CNS) [22].
The metabolic function of leptin is to serve as a sensor of
body fat stores for the CNS. Elevation of blood leptin due
to calorie intake, whether short-term or long-term, in a lean
person normally suppresses food intake, whereas decreased
leptin levels due to fasting or loss of adipose tissue lead to
increased food intake [23]. In obesity however, elevated lep-
tin does not lead to the expected responses in weight con-
trol. This is thought to be due to disturbed leptin signaling,
also called leptin resistance. Elevated SOCS-3 expression in
the CNS is proposed to be the primary mechanism that
causes leptin resistance and subsequent failure in con-
trolling food intake in obesity [22]. Consistently, leptin-
deficient mice develop severe obesity [24], whereas
SOCS-3 conditional knockout mice are resistant to
diet-induced obesity [25]. In humans, genetic leptin defi-
ciency also causes severe obesity, though leptin and leptin-
receptor-related mutations are extremely rare [26].
SOCS-3 is also expressed in cartilage [27–29], and we
reported previously that its expression is lower in carti-
lage from obese patients with OA than from non-obese
patients [8]. That led us to hypothesize that SOCS-3
could be a significant mechanism behind the variable
leptin responsiveness in cartilage samples from different
donor patients. We addressed the hypothesis by investi-
gating SOCS-3 expression and leptin responsiveness in
cartilage samples obtained from 97 patients with OA. In
addition, the role of SOCS-3 expression in leptin signa-
ling was studied by downregulating SOCS-3 by siRNA
in chondrocyte cultures.
Methods
Cartilage and cell cultures
Cartilage and synovial fluid (SF) samples were collected
from 97 patients with OA who were undergoing knee
replacement surgery. All patients fulfilled the American
College of Rheumatology classification criteria for OA
[30]. Cartilage samples were processed for tissue culture
as previously described [15]. Cartilage pieces were incu-
bated for 42 hours with or without leptin (10 μg/ml).
The concentration of leptin used was chosen based on our
previous studies and on existing literature [15, 17–19].
Recombinant human leptin was purchased from R&D
Systems Europe Ltd, Abindgon, UK. Synovial fluid (SF)
samples from the corresponding patients were also col-
lected at the beginning of the arthroplasty. The SF sam-
ples were centrifuged at 4000 g at 4 °C and supernatants
were collected and kept at −70 °C until assayed.
The immortalized murine H4 chondrocyte cell line
[31], developed in the Laboratory of Experimental
Rheumatology, University Medical Center, Nijmegen, The
Netherlands, was used in the siRNA experiments. The
chondrocytes were cultured at 37 °C in humidified 5 % car-
bon dioxide atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) with L-glutamine and Ham’s F-12
medium (1:1) supplemented with 5 % fetal bovine serum
(all obtained from Lonza Group Ltd, Basel, Switzerland).
Immunoassays and nitrite measurements
Concentrations of MMP-1, MMP-3, MMP-13 and IL-6
were determined by immunoassays with commercial re-
agents according to the protocol provided by the manu-
facturer (human total MMP-1, human total MMP-3,
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human total MMP-13, mouse total MMP-3 and mouse IL-
6 ELISA kits were from R&D Systems; human IL-6 ELISA
kit was from Sanquin, Amsterdam, The Netherlands;
MMP-1 in SF was determined by Multiplex bead array,
Fluorokine® Human MMP Multi Analyte Profiling Base
Kit, purchased from R&D systems). Nitrite, stable metabo-
lite of nitric oxide (NO), was measured in the culture
media by the Griess reaction [32]. The cartilage culture
media samples were filtered through Amicon Ultra 10-K
filters (from Millipore, Cork, Ireland) at 14,000 g prior to
the Griess analysis in order to remove large proteins that
might interfere with the Griess analysis.
RNA isolation and quantitative reverse transcription/
polymerase chain reaction
Culture medium was removed at the indicated time
points and total RNA of H4 chondrocytes was extracted
with GenElute™ Mammalian Total RNA Miniprep kit
(Sigma-Aldrich, St Louis, MO, USA). Total RNA was
treated with DNAse (Fermentas UAB, Vilnius, Lithuania)
and reverse-transcribed to cDNA using TaqMan Reverse
Transcription reagents and random hexamers (Applied
Biosystems, Foster City, CA, USA). cDNA obtained from
the RT reaction was diluted 1:20 with RNAse-free water
and subjected to quantitative PCR using TaqMan Universal
PCR Master Mix and the ABI Prism 7000 Sequence de-
tection system (Applied Biosystems). Primers and probes
for SOCS-3, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), iNOS, IL-6 and MMP-13 were obtained from
Metabion International AG (Martinsried, Germany). The
primer and probe sequences and concentrations (Table 1)
were optimized according to the manufacturer’s instruc-
tions in TaqMan Universal PCR Master Mix Protocol part
number 4304449 revision C. The expression of mouse
MMP-3 mRNA was measured using TagMan Gene Ex-
pression Assay (Mm00440295_m1, Applied Biosystems).
PCR reaction parameters were as follows: incubation
at 50 °C for 2 minutes, incubation at 95 °C for 10 mi-
nutes, and thereafter 40 cycles of denaturation at 95 °C
for 15 s and annealing and extension at 60 °C for 1 mi-
nute. Each experimental reaction was performed in du-
plicate. The relative mRNA levels of SOCS-3, GAPDH,
iNOS, IL-6 and MMP-13 were quantified using the
standard curve method as described in Applied Biosys-
tems User Bulletin number 2. To calculate the relative
expression of MMP-3 mRNA, the 2(−ΔΔCT) method [33]
was used. According to the method, the cycle threshold
(CT) values for MMP-3 mRNA expression in each sam-
ple were normalized to the CT values of GAPDH mRNA
in the same sample.
Western blot
Preparation of cell lysates, SDS-polyacrylamide gel elec-
trophoresis and western blot analysis were carried out as
previously described [15]. Mouse monoclonal SOCS-3
antibody (sc-51699), rabbit polyclonal iNOS antibodies
(sc-651 and sc-650), goat polyclonal cyclooxygenase-2
(COX-2) antibody (sc-1745) and rabbit polyclonal β-actin
antibody (sc-1615R), and secondary horseradish peroxidase
(HRP)-conjugated goat anti-mouse (sc-2005), goat anti-
rabbit (sc-2004) and donkey anti-goat (sc-2020) antibodies
were all from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Rabbit polyclonal MMP-13 antibody (ab39012) was
from Abcam (Cambridge, MA, USA). Leptin-induced
iNOS and COX-2 expression was determined by running
the control and leptin-induced samples side by side and
the result is given as fold of change in the β-actin-
normalized densitometry value of the leptin-induced versus
the control sample.
Downregulation of SOCS-3 expression by siRNA
H4 murine chondrocytes were seeded at 1 × 105 cells/well
in 24-well plates. Cells were incubated for 24 hours and
transfected with SOCS-3 siRNA or with non-targeting
control siRNA. On-Target SMART pool SOCS-3-specific
siRNA (targeting sequences of GGCUAGGAGACUCGC
CUUA, GGACCAAGAACCUACGCAU, CUAAUGAAA
CCUCGCAGAU and GAAGGGAGGCAGAUCAACA)
and siGENOME Non-Targeting siRNA were used at 100
nM to transfect the cells using DharmaFECT 1. All trans-
fection reagents were from Thermo Scientific Dharmacon
(Lafayette, CO, USA) and transfection was carried out
according to the manufacturer’s protocol. The experi-
ments were started 48 hours after the transfection by add-
ing leptin (10 μg/ml) (mouse recombinant leptin from
R&D systems) in fresh culture medium.
Statistical analysis
The chi-square test, unpaired t test and Mann–Whitney
test (where appropriate) were used to analyze differences
between subgroups of the patients. The Wilcoxon test
was used to calculate the significance of leptin-induced
effects in the cartilage culture.
To analyze the differences in leptin responsiveness in
relation to SOCS-3 expression, the samples on each
western blot gel were divided to two equal sized groups
(low SOCS-3 or high SOCS-3) according to SOCS-3 ex-
pression. Median leptin responses, measured as change
in the production of MMP-1, MMP-3, MMP-13, IL-6
and NO in the leptin-treated versus control sample,
and as fold of change in the expression of iNOS and
COX-2, were compared between the low SOCS-3 and
the high SOCS-3 groups. Possible intergel differences
in SOCS-3 expression were controlled by analysis of
variance (ANOVA) in which the leptin response vari-
able (e.g., leptin-induced change in production of
MMP-1) was set as a dependent variable, western blot
gel (1 to 8) as a grouping variable and SOCS-3
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expression as a continuous variable as a covariate. Associ-
ations were further tested by adjusting for BMI and age.
Correlation between the factors of interest in SF were de-
termined by Pearson’s correlation analysis. The associations
between MMPs or IL-6 and leptin in SF, and SOCS-3 ex-
pression in cartilage were further analyzed by ANOVA
modeling, by including the variable of interest (SF MMP-1,
MMP-3 or IL-6) as a dependent variable, leptin in SF and
SOCS-3 expression in the cartilage as covariates and gel
number as a grouping factor. The analysis was done in
BMI subgroups (obese, BMI >30 kg/m2; non-obese, BMI
<30 kg/m2). Natural logarithms were formed of the leptin
response values, SOCS-3 expression levels and SF levels of
the measured variables where appropriate in order to have
normally distributed variables for the ANOVA modeling
and for the correlation analyses.
The data were analyzed by IBM SPSS Statistics 19 (IBM
Corporation, NY, USA) and Graph-Pad InStat version 3.00
software (GraphPad Software Inc., San Diego, CA, USA).
The results of the siRNA experiments are presented as
means (SEM). The statistical significance of these data was
calculated by two-way ANOVA with Bonferroni multiple
comparisons post-test using Graph-Pad Prism 5 for Win-
dows version 5.04 (GraphPad Software Inc.). Differences
were considered statistically significant at p < 0.05.
Results
Leptin-induced production of proinflammatory and
catabolic factors in osteoarthritic cartilage in relation to
clinical factors and SOCS-3 expression
Patient characteristics and leptin responses in the cultured
cartilage across the whole study population and in the
obese (BMI >30 kg/m2) and non-obese subgroups are
presented in Table 2. Leptin significantly enhanced the
expression of MMP-1, MMP-3, MMP-13, IL-6, iNOS and
COX-2 and NO production in OA cartilage ex vivo (Fig. 1).
However, there was considerable variation in these re-
sponses between the samples from different donor patients
(Table 2). There were no statistically significant differences
in the leptin responses between obese and non-obese
patients (Table 2), and neither did the leptin responses
correlate with age, sex or radiographic scaling of OA.
When the patients were divided into subgroups accor-
ding to SOCS-3 expression in the cartilage, leptin-induced
changes in the expression/production of MMP-1, MMP-3,
MMP-13, IL-6, NO, iNOS and COX-2 in the cartilage were
significantly greater in the samples with low SOCS-3 ex-
pression than in the samples with high SOCS-3 expression
(Fig. 2). This suggests that the level of SOCS-3 expression
determinates the magnitude of leptin-induced inflamma-
tory responses. The results remained statistically significant
(p < 0.05) for the responses in the expression of MMP-3,
MMP-13, IL-6, NO, iNOS and COX-2, and almost signifi-
cant for response in the expression of MMP-1 (p = 0.10) in
the ANOVA modeling after controlling for intergel vari-
ation, BMI and age.
Synovial fluid levels of MMPs and IL-6 in relation to SF
leptin and SOCS-3 expression in cartilage from patients
with OA
SF samples were obtained from 90 of the 97 patients.
Obese patients had significantly higher SF leptin than
non-obese patients, while SF MMP-1 and MMP-3 did
not significantly differ between obese and non-obese
Table 1 Primer and probe sequences for quantitative RT-PCR
Gene Oligunucleotide Sequence Conc. (nM)
Forward primer GCATGGCCTTCCGTGTTC 300
Mouse GAPDH Reverse primer GATGTCATCATACTTGGCAGGTTT 300
Probe TCGTGGATCTGACGTGCCGCC 150
Forward primer GCGGGCACCTTTCTTATCC 300
Mouse SOCS-3 Reverse primer AAGCTGCCCCCCTCACA 300
Probe CTCGGACCAGCGCCACTTCTTCA 150
Forward primer CCTGGTACGGGCATTGCT 300
Mouse iNOS Reverse primer GCTCATGCGGCCTCCTT 300
Probe CAGCAGCGGCTCCATGACTCCC 150
Forward primer TCGGAGGCTTAATTACACATGTTC 900
Mouse IL-6 Reverse primer CAAGTGCATCATCGTTGTTCATAC 300
Probe CAGAATTGCCATTGCACAACTCTTTTCTCA 200
Forward primer TTGTGTTTGCAGAGCACTACTTGA 900
Mouse MMP-13 Reverse primer AACTGTGGAGGTCACTGTAGACTTCTT 900
Probe CATCCTGCGACTCTTGCGGGAATC 250
SOCS-3 suppressor of cytokine signaling-3, iNOS inducible nitric oxide synthase, IL-6 interleukin-6, MMP-13 matrix metalloproteinase-13, Conc. concentration
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patients (Table 2). Leptin correlated positively with MMP-
1 and with MMP-3 in SF from obese but not from non-
obese patients (Fig. 3). In ANOVA modeling, leptin con-
centrations in SF and SOCS-3 expression in cartilage sig-
nificantly explained levels of SF MMP-1 and MMP-3 in
the obese but not in the non-obese group (Table 3) point-
ing to obesity-related association of leptin and SOCS-3 in
OA pathophysiology. In addition, SF IL-6 levels were ex-
plained by SOCS-3 in the obese but not in the non-obese
group, while leptin did not significantly explain SF IL-6
levels in either of the BMI subgroups (Table 3).
SOCS-3 modulates leptin responses in chondrocytes
In order to investigate further the role of SOCS-3 in the
regulation of leptin-induced responses in chondrocytes,
we used siRNA to downregulate SOCS-3 in the H4 chon-
drocyte cell line. H4 chondrocytes expressed SOCS-3
mRNA at relatively high levels and it was reduced by ap-
proximately 80 % in the SOCS-3-siRNA-treated cells
when compared to the cells transfected with control
siRNA. Leptin had a clear effect on inducing MMP-3,
MMP-13, IL-6 and iNOS expression in the SOCS-3-
deficient cells, whereas in the control siRNA-treated cells
leptin did not have any statistically significant effect on
the production of these factors (Fig. 4), confirming that
SOCS-3 negatively regulates leptin-induced proinflamma-
tory responses in chondrocytes.
Discussion
Leptin has been shown to have detrimental effects on
cartilage metabolism in several studies [6, 11–19]. How-
ever, considerable variation in leptin responsiveness
between cartilage/chondrocytes from different patients
has been observed. Our present results indicate that a
significant mechanism behind the differential leptin
responsiveness could be SOCS-3.
SOCS-3 is a known negative regulator of inflammatory
signals [20]. Its role in controlling the effects of leptin in
chondrocytes has not been previously investigated, but it
has been reported to regulate the responses of leptin in
the CNS [22]. In the present study we show, for the first
time, that SOCS-3 regulates the proinflammatory and
catabolic effects of leptin in chondrocytes. This was
demonstrated as greater leptin responsiveness in cartil-
age explants with low SOCS-3 expression in comparison
to lower leptin responsiveness in the explants with high
SOCS-3 expression. The causality of this association was
illustrated by downregulation of SOCS-3 by siRNA in
the chondrocyte cell line, which led to increased leptin-
induced expression of proinflammatory and catabolic
genes. In addition, SF leptin levels were shown to be
positively associated, and cartilage SOCS-3 expression
negatively associated with SF MMP levels in obese, but
not in non-obese patients with OA. This points to dys-
regulation of the leptin-SOCS-3 axis, especially in obese
Table 2 Patient characteristics and leptin responses in cartilage cultures in the whole study population and compared across body
mass index subgroups
All Non-obese, BMI <30 kg/m2 Obese, BMI >30 kg/m2
n = 97 n = 49 n = 48 P
Gender (female/male)a 60/37 26/23 34/14 0.072
Body mass index (kg/m2)b 30.9 (6.1) 26.2 (2.4) 35.7 (4.6) <0.001
Age (years)b 69.8 (10.0) 72.8 (9.7) 66.8 (9.4) 0.003
Synovial fluid leptin (ng/ml)c, d 12.8 (17.8) 7.6 (11.0) 21.5 (26.7) <0.001
Synovial fluid IL-6 (pg/ml)c, d 118.9 (196.0) 126.8 (204.3) 114.0 (280.2) 0.784
Synovial fluid MMP-1 (ng/ml)c, d 14.4 (25.7) 10.4 (16.6) 18.1 (27.3) 0.325
Synovial fluid MMP-3 (ng/ml)c, d 649.5 (929.6) 591.6 (571.0) 764.9 (1159.0) 0.106
Leptin response in cartilage
MMP-1 (change pg/mg cartilage)c 145.8 (247.1) 123.2 (253.6) 150.0 (258.3) 0.773
MMP-3 (change ng/mg cartilage)c 5.2 (8.8) 6.0 (8.6) 4.9 (10.2) 0.920
MMP-13 (change pg/mg cartilage)c 5.8 (13.6) 6.3 (11.8) 5.4 (15.9) 0.983
IL-6 (change pg/mg cartilage)c 123.2 (310.2) 114.6 (295.1) 130.9 (312.0) 0.740
NO (change pmol/mg cartilage)c 44.5 (133.4) 31.0 (125.8) 52.2 (140.0) 0.359
iNOS (fold of increase)c, e 11.7 (160.6) 5.4 (143.1) 15.2 (209.6) 0.501
COX-2 (fold of increase)c, e 6.9 (18.4) 7.1 (15.0) 6.4 (22.6) 0.748
aValues are numbers of female/male subjects; p value was calculated for comparison between non-obese and obese subjects using the chi-square test. bValues are
mean (SD); p values were calculated for comparison between non-obese and obese subjects using the unpaired t test. cValues are median (IQR); p values
were calculated for comparison between non-obese and obese subjects using the Mann–Whitney test. dSynovial fluid sample was obtained from 90 patients.
eNumbers of patients (non-obese/obese) in the analysis were 26/31 for inducible nitric oxide synthase (iNOS) and 25/29 for cyclooxygenase-2 (COX-2). MMP matrix
metalloproteinase, IL interleukin, NO nitric oxide
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individuals, and to a possible obesity-related pathogenic
mechanism in OA.
In the present study we observed a positive association
between leptin levels and matrix metalloproteinases in
SF that was only present in the obese patients with OA.
However, obesity did not explain the differential leptin
responsiveness in the cartilage culture experiments, un-
like in the study by Pallu et al. where greater leptin
Fig. 1 Effect of leptin on the production of matrix metalloproteinase-1 (MMP-1) (a), MMP-3 (b), MMP-13 (c), interleukin-6 (IL-6) (d), nitric oxide (NO) (e)
and on the expression of inducible nitric oxide synthase (iNOS) (f) and cyclooxygenase-2 (COX-2) (g) in cartilage from patients with osteoarthritis (OA).
Cartilage samples from 97 patients with OA were cultured with and without leptin (10 μg/ml) for 42 hours. Concentrations of MMP-1, MMP-3, MMP-13
and IL-6 were measured by ELISA; NO production was determined as its metabolite nitrite by the Griess reaction and iNOS and COX-2 proteins by
western blotting. The circles represent the medians. The whiskers represent 95 % confidence interval of the median. Statistical significance was calculated
using the Wilcoxon test; ***p< 0.001
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Fig. 2 Leptin-induced production/expression of matrix metalloproteinase-1 (MMP-1) (a), MMP-3 (b), MMP-13 (c), interleukin-6 (IL-6) (d), nitric oxide
(NO) (e), inducible nitric oxide synthase (iNOS) (f) and cyclooxygenase-2 (COX-2) (g) in cartilage from patients with osteoarthritis (OA) in subgroups
stratified by suppressor of cytokine signaling-3 (SOCS-3) expression in the non-treated cartilage. Human osteoarthritic cartilage was cultured with
leptin (10 μg/ml) for 42 hours. Concentrations of MMP-1, MMP-3, MMP-13 and IL-6 were measured by ELISA, NO was determined as its metabolite
nitrite by the Griess reaction and iNOS and COX-2 proteins were analyzed by western blotting. The circles represent the median change in the
leptin-induced effects. The whiskers represent the 95 % confidence interval of the median. Numbers of patients from whom the cartilage samples
were collected are indicated. Statistical significance was calculated using the Mann–Whitney test; *p < 0.05, **p < 0.01
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Fig. 3 Correlation between leptin and matrix metalloproteinase-1 (MMP-1) and MMP-3 in non-obese (a) and obese (b) patients with osteoarthritis.
Leptin and MMPs were measured in synovial fluid (SF) by immunoassay. Natural logarithms (LN) were formed of the SF levels of leptin and MMPs
in order to have normally distributed variables for the Pearson correlation analysis. Correlation coefficients (r) and p values are indicated. Samples
were collected from 90 patients (non-obese, BMI <30 kg/m2, n = 44; obese, BMI >30 kg/m2, n = 46)
Table 3 Associations between interleukin-6 (IL-6), matrix metalloproteinase-1 (MMP-1), MMP-3 and leptin in synovial fluid and
suppressor of cytokine signaling-3 (SOCS-3) expression in cartilage from non-obese and obese patients with osteoarthritis
Non-obese, BMI <30 kg/m2 Obese, BMI >30 kg/m2
Dependent variable Covariates R2 adjusted P R2 adjusted P
LN (SF MMP-1) 0.15 0.30
LN SOCS-3 0.818 0.007
LN (SF leptin) 0.884 0.023
LN (SF MMP-3) 0.03 0.27
LN SOCS-3 0.608 0.004
LN (SF leptin) 0.733 0.015
LN (SF IL-6) −0.05 0.20
LN SOCS-3 0.945 0.003
LN (SF leptin) 0.808 0.466
P values are calculated for covariates in analysis of variance modeling. The model is controlled for intergel variation in SOCS-3 expression levels. Analysis was
performed in body mass index (BMI) subgroups. Natural logarithms (LN) were formed where appropriate. SF synovial fluid
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Fig. 4 The effect of silencing of suppressor of cytokine signaling-3 (SOCS-3) by siRNA on leptin-induced expression of matrix metalloproteinase-3
(MMP-3) (a, e), MMP-13 (b, f), interleukin-6 (IL-6) (c, g) and inducible nitric oxide synthase (iNOS) (d, h) in H4 murine chondrocytes. The cells were
transfected with SOCS-3 siRNA or non-targeting siRNA (siNEG) and treated with leptin (10 μg/ml) for 4 (c, d), 8 (a, b, h) or 24 (e-g) hours. mRNA
expression (a-d) was determined by quantitative RT-PCR, the levels of MMP-3 (e) and IL-6 (g) in the culture media supernatants by ELISA, and
MMP-13 (f) and iNOS (h) expression in the chondrocyte lysates by western blotting. Results are expressed as means ± SEM; n = 6 (a-e and g) and
n = 3 (f, h). MMP-3 protein level in siNEG and in non-treated SOCS-3 siRNA samples was below the detection limit and is set as half of the lowest
standard. Representative bands of the western blots are shown. Statistical analysis was carried out by two-way analysis of variance with Bonferroni
multiple comparisons post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001. n.s. not significant
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response in MMP-13 mRNA expression in primary
chondrocytes obtained from obese in comparison with
non-obese patients with OA was reported [17]. The dif-
ferences between these two studies could be explained
by differential experimental conditions. Instead of pri-
mary chondrocytes we used pieces of cartilage, which
provides a more natural environment for the chondro-
cytes in the culture. In addition, we used higher concen-
trations of leptin to ensure adequate penetration of
leptin into the cartilage explant tissue. Of note, in the
experimental studies, all cartilage explants were treated
with the same leptin concentration in the culture in con-
trast to the in vivo situation where leptin concentration
in SF is highly relative to BMI [5, 6, 8].
Other factors that might affect leptin responsiveness
in vivo and that could contribute to the differential lep-
tin responsiveness in cartilage from individual donors as
seen in the present study, include functional leptin re-
ceptor (Ob-Rb) expression in chondrocytes and the
amount of soluble leptin reseptor (sOb-R) in SF or in
environment surrounding the chondrocytes. We previ-
ously reported that the level of soluble leptin receptor,
that is thought to bind active leptin, is decreased in SF
in obese subjects [8]. The expression of Ob-Rb has been
shown to be unaffected in obesity [6, 17], whereas it has
been reported to be increased in severely damaged car-
tilage [5, 6]. In vivo, all of these mechanisms are likely to
contribute to the quantity of leptin-evoked effects, obes-
ity seemingly favoring enhanced responses in many
ways.
Leptin binding to its receptor leads to activation of mul-
tiple intracellular pathways including the Janus kinase-2
(JAK2)-STAT3, mitogen-activated protein kinase (MAPK),
nuclear factor (NF)-kB and PI3K/Akt pathways, all of which
have been shown to be involved in the leptin-induced
production of proinflammatory factors by chondrocytes
[11–15, 18, 19]. SOCS-3 has been shown to inhibit not only
the STAT3 pathway, but also the extracellular signal-related
kinase (Erk)1/2 and NF-kB pathways [34, 35], providing a
possible mechanistic explanation for how leptin-induced
responses could be modulated by SOCS-3 in chondrocytes.
Interestingly Pallu et al. report higher leptin-induced activa-
tion of STAT3 in chondrocytes from obese than from non-
obese patients [17], which could be a consequence of de-
creased SOCS-3 expression, and may explain the differen-
tial leptin responsiveness in obese individuals observed in
their study. However, the involvement of SOCS-3 expres-
sion in explaining increased STAT3 activation in chondro-
cytes needs to be further studied.
According to the data in the present study, SOCS-3
appears to be a cartilage-protective factor in OA, as low
SOCS-3 expression was associated with enhanced proin-
flammatory and catabolic effects of leptin. Here we in-
vestigated the role of SOCS-3 only in leptin signaling,
but its role in OA may be much wider, as it can be involved
in the regulation of the inflammatory responses induced by
a variety of cytokines in multiple cell types in the joint [27,
36]. To our knowledge, only a few groups have previously
investigated SOCS-3 expression in chondrocytes. Van de
loo et al. reported that SOCS-3 overexpression inhibits
lipopolysachharide (LPS)-induced NO production in chon-
drocytes [29] supporting the idea that SOCS-3 has a similar
function in chondrocytes as in white blood cells, that is, to
limit excessive inflammatory response. The role of SOCS-3
in arthritis has been studied in animal models by a few
groups and the existing data support the idea that SOCS-3
has a protective role in arthritis.
In a study by Shouda et al. SOCS-3 overexpression by
intra-articular adenoviral gene transfer prevented the de-
velopment of collagen-induced arthritis in mice [37].
Veenbergen et al. reported similar results [38]. In their
study SOCS-3 was delivered into the animals also by
adenovirus gene transfer, but intravenously. Conversely,
in a study by Wong et al. conditional deletion of SOCS-3
in the hematopoietic and endothelial cell compartment
led to particularly severe arthritis in a mouse model [39],
supporting the importance of SOCS-3 as a negative
regulator of inflammation. In the first two studies men-
tioned [37, 38] the target cells of SOCS-3 overexpression
were supposed to be synoviocytes, antigen-presenting
cells and possibly also B and T lymphocytes. In OA, chon-
drocytes are thought to be the central cell population that
produces pathogenic factors; however, synoviocytes and
inflammatory cells are also assumed to contribute to the
inflammatory process. The present results indicate that
SOCS-3 also modulates the inflammatory response in
chondrocytes and thus, could be a promising drug target
in the prevention/treatment of OA.
It is unclear, what explains the differential SOCS-3 ex-
pression in the cartilage from patients with OA in the
present study. Cytokines including IL-1, IL-6, IFN-γ and
TNF-α are all known inducers of SOCS-3 [40] and can
be also found in the SF of affected joints in OA [41].
Interestingly, anti-inflammatory cytokine IL-10, statins
and drugs that elevate cAMP are also known to induce
SOCS-3 expression [40]. As it is induced by multiple fac-
tors, it is likely that the level of SOCS-3 expression in
chondrocytes is defined by a complex net effect of proin-
flammatory and anti-inflammatory factors. SOCS-3 ex-
pression has been reported to be elevated in chondrocytes
from patients with OA and RA in comparison to patients
with femoral neck fracture without arthritis [29]; this is
consistent with previous findings in other tissues, suggest-
ing that SOCS-3 expression is elevated at the sites of in-
flammation, possibly as a regulatory mechanism to limit
excessive inflammation response [42]. It is also possible
that SOCS-3 expression would be affected by genetic poly-
morphisms in SOCS-3. There are two single nucleotide
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polymorphisms (SNPs) previously described in human
SOCS-3, one in the promoter region and another in the
exon 1 of SOCS-3. However, in a large case–control study
by Hölter et al. [43] these SNPs were found to have no
effect on the expression/function of SOCS-3 and there
were no differences in the frequency of these SNPs
between overweight and underweight individuals.
In the present study leptin was positively associated
and SOCS-3 was negatively associated with MMP levels
in SF in obese but not in non-obese patients with OA,
further confirming the importance of the leptin-SOCS-3
axis in cartilage metabolism and its possible significance
in obesity-induced OA. Obesity is a significant risk fac-
tor for OA. In a Finnish population-based long-term
follow-up study, a sevenfold risk of developing knee OA
was reported in obese individuals with BMI >30 kg/m2,
as compared with subjects with BMI <25 kg/m2 [44].
Several epidemiological and cross-sectional studies have
investigated the association between leptin and the
prevalence/incidence of OA, pain in OA and structural
changes in the cartilage in OA [45–55].
Leptin is linked to OA in many of those studies but the
results are partly conflicting. The differences might arise
from the research frame and also from difficulty in differ-
entiating the impact of body fat stores and leptin by statis-
tical means, as these factors correlate strongly with one
another. Karvonen-Gutirrez et al. used sophisticated sta-
tistical analysis, by adjusting their data for residuals from
the regression of leptin on BMI, aiming to control their
data for factors other than the metabolic component of
BMI [54]. Interestingly, in their population-based study
leptin predicted cartilage defects, as detected by magnetic
resonance imaging (MRI) at the 10-year follow-up [54].
Another way to separate the effect of obesity and lep-
tin was attempted by the use of leptin-deficient animals.
In fact, Griffin et al. showed that leptin-deficient C57BL
mice with diet-induced obesity did not develop OA like
the corresponding wild-type mice, suggesting that obes-
ity without increased leptin does not lead to OA [56]. In
the present study we analyzed patients with OA in BMI
subgroups (obese and non-obese) and interestingly, leptin
correlated with MMP enzymes in SF only in the obese pa-
tients. This finding further supports the role of leptin in
connecting obesity and OA. OA is a heterogenic disease
with many known risk factors and it is likely that cartilage
destruction in non-obese individuals is driven by patho-
genic factors other than leptin. We also showed here that
SOCS-3 expression in cartilage is negatively associated
with SF levels of IL-6 and MMPs, and this was also seen
only in the obese group, suggesting that SOCS-3 expres-
sion might be inadequate in the cartilage of obese indivi-
duals. Our previous finding that SOCS-3 expression in
OA cartilage is decreased in obese compared to non-
obese patients [8] supports this idea.
Conclusions
As a summary of this work, we demonstrated that
SOCS-3 negatively modulates the pathogenic effects of
leptin in chondrocytes. In addition, SOCS-3 expression
in cartilage was negatively associated and synovial fluid
leptin levels positively associated with synovial fluid MMP
concentrations in obese, but not in non-obese patients
with OA. This supports the harmful role of leptin and
meaningful regulator role of SOCS-3 in obesity-related
OA. Considering these factors in future studies could help
to recognize new targets in the treatment and prevention
of obesity-related OA.
Abbreviations
ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs;
ANOVA: analysis of variance; BMI: body mass index; cDNA: complementary
DNA; CNS: central nervous system; COX-2: cyclooxygenase-2; CT: cycle
threshold; DMEM: Dulbecco’s modified Eagle’s medium; ELISA: enzyme-linked
immunosorbent assay; Erk1/2: extracellular signal-regulated kinase ½;
GAPDH: glyceraldehyde-3-phosphate dehydrogenase; gp130: glycoprotein 130;
IFN: interferon; IL: interleukin; iNOS: inducible nitric oxide synthase; JAK: Janus
kinase; LN: natural logarithm; LPS: lipopolysaccharide; MAPK: mitogen-activated
protein kinase; MMP: matrix metalloproteinase; MRI: magnetic resonance
imaging; mRNA: messenger RNA; NF-kB: nuclear factor kappa B; NO: nitric oxide;
OA: osteoarthritis; Ob-Rb: functional leptin receptor; PCR: polymerase chain
reaction; PGE2: prostaglandin E2; PI3K: phosphoinositide 3-kinase; SEM: standard
error of the mean; SF: synovial fluid; siRNA: small interfering RNA; SNP: single
nucleotide polymorphism; sOb-R: soluble leptin receptor; SOCS-3: suppressor of
cytokine signaling-3; STAT: a signal transducer and activator of transcription;
TNF: tumor necrosis factor
Acknowledgements
The excellent technical assistance of Meiju Kukkonen, Marja-Leena Lampén,
Marja Jousimies, Jan Koski, Mirva Järvelä-Stolting, Nea Bister and Ella Lehto,
and the skillful secretarial help of Heli Määttä are greatly acknowledged.
Statistician Heini Huhtala is warmly thanked for her advice on the statistical
analysis.
Funding
This study was financially supported by The Academy of Finland, the Competitive
Research Funding of the Pirkanmaa Hospital District, Päivikki and Sakari Sohlberg
Foundation, the Orion-Farmos Research Foundation and the Scandinavian
Rheumatology Research Foundation. AKK is a graduate student in the
Tampere Graduate Program in Biomedicine and Biotechnology.
Authors’ contributions
AKK was involved in the conception and design of the study, the laboratory
analyses, calculation of the results and interpretation of the data and she
drafted the manuscript. KV was involved in the conception and design of
the study, the laboratory analyses, calculation of the results, interpretation of
the data and drafting the manuscript. RK was involved in the conception and
design of the siRNA experiments, calculation of the results, interpretation of the
results and revising the manuscript. TM was involved in the conception and
design of the study, selecting the patients, acquiring the patient samples,
interpretation of the data and revising the manuscript. EM was involved in the
conception and design of the study, interpretation of the data and drafting the
manuscript. All authors approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All patients gave their informed consent to the study. The study was approved
by the Ethics Committee of Tampere University Hospital and it was carried out
in accordance with the Declaration of Helsinki.
Koskinen-Kolasa et al. Arthritis Research & Therapy  (2016) 18:215 Page 11 of 13
Author details
1The Immunopharmacology Research Group, University of Tampere School
of Medicine and Tampere University Hospital, Tampere, Finland. 2Coxa
Hospital for Joint Replacement, Tampere, Finland.
Received: 4 May 2016 Accepted: 5 September 2016
References
1. Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and
osteoarthritis. Applications for prevention and treatment. Basic Clin Pharmacol
Toxicol. 2014;114:103–8.
2. Scotece M, Conde J, Vuolteenaho K, Koskinen A, Lopez V, Gomez-Reino J,
Lago F, Moilanen E, Gualillo O. Adipokines as drug targets in joint and bone
disease. Drug Discov Today. 2014;19:241–58.
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue. Nature. 1994;
372:425–32.
4. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR,
Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin
concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:
292–5.
5. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, Pottie P.
Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 2003;48:
3118–29.
6. Simopoulou T, Malizos KN, Iliopoulos D, Stefanou N, Papatheodorou L,
Ioannou M, Tsezou A. Differential expression of leptin and leptin's receptor
isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic
cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage. 2007;15:872–83.
7. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects
MMP-13 expression in osteoarthritic chondrocytes: possible molecular target
for osteoarthritis therapeutic intervention. Ann Rheum Dis. 2007;66:1616–21.
8. Vuolteenaho K, Koskinen A, Moilanen T, Moilanen E. Leptin levels are
increased and its negative regulators, SOCS-3 and sOb-R are decreased in
obese patients with osteoarthritis: a link between obesity and osteoarthritis.
Ann Rheum Dis. 2012;71:1912–3.
9. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of
osteoarthritis of the knee in older adults: a systematic review and meta-
analysis. Osteoarthritis Cartilage. 2010;18:24–33.
10. Kloppenburg M, Kwok WY. Hand osteoarthritis–a heterogeneous disorder.
Nat Rev Rheumatol. 2011;8:22–31.
11. Otero M, Gomez Reino JJ, Gualillo O. Synergistic induction of nitric oxide
synthase type II: in vitro effect of leptin and interferon-gamma in human
chondrocytes and ATDC5 chondrogenic cells. Arthritis Rheum. 2003;48:404–9.
12. Otero M, Lago R, Lago F, Reino JJ, Gualillo O. Signalling pathway involved in
nitric oxide synthase type II activation in chondrocytes: synergistic effect of
leptin with interleukin-1. Arthritis Res Ther. 2005;7:R581–91.
13. Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O.
Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma
synergistic NOS type II induction in chondrocytes. Life Sci. 2007;81:1452–60.
14. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC, Chiu YC, Fong
YC, Tang CH. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K,
Akt cascade and promotion of NF-kappaB/p300 binding in human synovial
fibroblasts. Cell Signal. 2008;20:1478–88.
15. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päivärinta U,
Moilanen T, Moilanen E. Leptin enhances synthesis of proinflammatory
mediators in human osteoarthritic cartilage–mediator role of NO in leptin-
induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009;2009:
345838.
16. Bao JP, Chen WP, Feng J, Hu PF, Shi ZL, Wu LD. Leptin plays a catabolic role
on articular cartilage. Mol Biol Rep. 2010;37:3265–72.
17. Pallu S, Francin PJ, Guillaume C, Gegout-Pottie P, Netter P, Mainard D,
Terlain B, Presle N. Obesity affects the chondrocyte responsiveness to leptin
in patients with osteoarthritis. Arthritis Res Ther. 2010;12:R112.
18. Koskinen A, Vuolteenaho K, Nieminen R, Moilanen T, Moilanen E. Leptin
enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic
cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA
patients. Clin Exp Rheumatol. 2011;29:57–64.
19. Hui W, Litherland GJ, Elias MS, Kitson GI, Cawston TE, Rowan AD, Young DA.
Leptin produced by joint white adipose tissue induces cartilage degradation
via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis.
2012;71:455–62.
20. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses.
Immunity. 2008;28:477–87.
21. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune
regulation. Nat Rev Immunol. 2007;7:454–65.
22. St-Pierre J, Tremblay ML. Modulation of leptin resistance by protein tyrosine
phosphatases. Cell Metab. 2012;15:292–7.
23. Park HK, Ahima RS. Leptin signaling. F1000Prime Rep. 2014;6:73. doi:10.
12703/P6-73.
24. Myers Jr MG. Leptin receptor signaling and the regulation of mammalian
physiology. Recent Prog Horm Res. 2004;59:287–304.
25. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T,
Chien KR, Yasukawa H, Yoshimura A. Socs3 deficiency in the brain elevates
leptin sensitivity and confers resistance to diet-induced obesity. Nat Med.
2004;10:739–43.
26. Dubern B, Clement K. Leptin and leptin receptor-related monogenic obesity.
Biochimie. 2012;94:2111–5.
27. Smeets RL, Veenbergen S, Arntz OJ, Bennink MB, Joosten LA, van den Berg
WB, van de Loo FA. A novel role for suppressor of cytokine signaling 3 in
cartilage destruction via induction of chondrocyte desensitization toward
insulin-like growth factor. Arthritis Rheum. 2006;54:1518–28.
28. de Andres MC, Imagawa K, Hashimoto K, Gonzalez A, Goldring MB, Roach
HI, Oreffo RO. Suppressors of cytokine signalling (SOCS) are reduced in
osteoarthritis. Biochem Biophys Res Commun. 2011;407:54–9.
29. van de Loo FA, Veenbergen S, van den Brand B, Bennink MB, Blaney-
Davidson E, Arntz OJ, van Beuningen HM, van der Kraan PM, van den
Berg WB. Enhanced suppressor of cytokine signaling 3 in arthritic
cartilage dysregulates human chondrocyte function. Arthritis Rheum.
2012;64:3313–23.
30. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke
TD, Greenwald R, Hochberg M. Development of criteria for the classification
and reporting of osteoarthritis. Classification of osteoarthritis of the knee.
Diagnostic and Therapeutic Criteria Committee of the American
Rheumatism Association. Arthritis Rheum. 1986;29:1039–49.
31. van Beuningen HM, Stoop R, Buma P, Takahashi N, van der Kraan PM, van den
Berg WB. Phenotypic differences in murine chondrocyte cell lines derived from
mature articular cartilage. Osteoarthritis Cartilage. 2002;10:977–86.
32. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum
SR. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal
Biochem. 1982;126:131–8.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods.
2001;25:402–8.
34. Hovsepian E, Penas F, Siffo S, Mirkin GA, Goren NB. IL-10 inhibits the NF-
kappaB and ERK/MAPK-mediated production of pro-inflammatory mediators
by up-regulation of SOCS-3 in Trypanosoma cruzi-infected cardiomyocytes.
PLoS One. 2013;8:e79445.
35. Chhabra JK, Chattopadhyay B, Paul BN. SOCS3 dictates the transition of
divergent time-phased events in granulocyte TNF-alpha signaling. Cell Mol
Immunol. 2014;11:105–6.
36. Isomäki P, Alanära T, Isohanni P, Lagerstedt A, Korpela M, Moilanen T,
Visakorpi T, Silvennoinen O. The expression of SOCS is altered in
rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1538–46.
37. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S,
Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A. Induction of the
cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating
inflammatory arthritis. J Clin Invest. 2001;108:1781–8.
38. Veenbergen S, Bennink MB, Affandi AJ, Bessis N, Biton J, Arntz OJ, van den
Berg WB, van de Loo FA. A pivotal role for antigen-presenting cells
overexpressing SOCS3 in controlling invariant NKT cell responses during
collagen-induced arthritis. Ann Rheum Dis. 2011;70:2167–75.
39. Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, Drake S, Kiu H,
McManus EJ, Alexander WS, Roberts AW, Wicks IP. SOCS-3 negatively
regulates innate and adaptive immune mechanisms in acute IL-1-
dependent inflammatory arthritis. J Clin Invest. 2006;116:1571–81.
40. White CA, Nicola NA. SOCS3: An essential physiological inhibitor of signaling
by interleukin-6 and G-CSF family cytokines. JAKSTAT. 2013;2:e25045.
41. Tsuchida AI, Beekhuizen M, ’t Hart MC, Radstake TR, Dhert WJ, Saris DB,
van Osch GJ, Creemers LB. Cytokine profiles in the joint depend on
pathology, but are different between synovial fluid, cartilage tissue and
Koskinen-Kolasa et al. Arthritis Research & Therapy  (2016) 18:215 Page 12 of 13
cultured chondrocytes. Arthritis Res Ther. 2014;16:441. doi:10.1186/
s13075-014-0441-0.
42. White GE, Cotterill A, Addley MR, Soilleux EJ, Greaves DR. Suppressor of
cytokine signalling protein SOCS3 expression is increased at sites of acute
and chronic inflammation. J Mol Histol. 2011;42:137–51.
43. Holter K, Wermter AK, Scherag A, Siegfried W, Goldschmidt H, Hebebrand J,
Hinney A. Analysis of sequence variations in the suppressor of cytokine
signaling (SOCS)-3 gene in extremely obese children and adolescents. BMC
Med Genet. 2007;8:21.
44. Toivanen AT, Heliövaara M, Impivaara O, Arokoski JP, Knekt P, Lauren H,
Kröger H. Obesity, physically demanding work and traumatic knee injury are
major risk factors for knee osteoarthritis–a population-based study with a
follow-up of 22 years. Rheumatology (Oxford). 2010;49:308–14.
45. Ding C, Parameswaran V, Cicuttini F, Burgess J, Zhai G, Quinn S, Jones G.
Association between leptin, body composition, sex and knee cartilage
morphology in older adults: the Tasmanian older adult cohort (TASOAC)
study. Ann Rheum Dis. 2008;67:1256–61.
46. Ku JH, Lee CK, Joo BS, An BM, Choi SH, Wang TH, Cho HL. Correlation of
synovial fluid leptin concentrations with the severity of osteoarthritis. Clin
Rheumatol. 2009;28:1431–5.
47. Gandhi R, Takahashi M, Smith H, Rizek R, Mahomed NN. The synovial fluid
adiponectin-leptin ratio predicts pain with knee osteoarthritis. Clin
Rheumatol. 2010;29:1223–8.
48. Berry PA, Jones SW, Cicuttini FM, Wluka AE, Maciewicz RA. Temporal
relationship between serum adipokines, biomarkers of bone and cartilage
turnover, and cartilage volume loss in a population with clinical knee
osteoarthritis. Arthritis Rheum. 2011;63:700–7.
49. Yusuf E, Ioan-Facsinay A, Bijsterbosch J, Klein-Wieringa I, Kwekkeboom J,
Slagboom PE, Huizinga TW, Kloppenburg M. Association between leptin,
adiponectin and resistin and long-term progression of hand osteoarthritis.
Ann Rheum Dis. 2011;70:1282–4.
50. de Boer TN, van Spil WE, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP,
Mastbergen SC. Serum adipokines in osteoarthritis; comparison with
controls and relationship with local parameters of synovial inflammation
and cartilage damage. Osteoarthritis Cartilage. 2012;20:846–53.
51. Massengale M, Reichmann WM, Losina E, Solomon DH, Katz JN. The
relationship between hand osteoarthritis and serum leptin concentration in
participants of the Third National Health and Nutrition Examination Survey.
Arthritis Res Ther. 2012;14:R132.
52. Massengale M, Lu B, Pan JJ, Katz JN, Solomon DH. Adipokine hormones and
hand osteoarthritis: radiographic severity and pain. PLoS One. 2012;7:e47860.
53. Karvonen-Gutierrez CA, Harlow SD, Mancuso P, Jacobson J, de Leon CFM,
Nan B. Association of leptin levels with radiographic knee osteoarthritis
among a cohort of midlife women. Arthritis Care Res (Hoboken). 2013;65:
936–44.
54. Karvonen-Gutierrez CA, Harlow SD, Jacobson J, Mancuso P, Jiang Y. The
relationship between longitudinal serum leptin measures and measures of
magnetic resonance imaging-assessed knee joint damage in a population
of mid-life women. Ann Rheum Dis. 2013;73:883–9.
55. Fowler-Brown A, Kim DH, Shi L, Marcantonio E, Wee CC, Shmerling RH,
Leveille S. The mediating effect of leptin on the relationship between body
weight and knee osteoarthritis in older adults. Arthritis Rheumatol. 2015;67:
169–75.
56. Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired
leptin signaling in mice does not cause knee osteoarthritis. Arthritis Rheum.
2009;60:2935–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Koskinen-Kolasa et al. Arthritis Research & Therapy  (2016) 18:215 Page 13 of 13
